Eisai/Biogen’s Leqembi (lecanemab) was fully approved in the US in July 2023, and Eli Lilly’s Kisunla (donanemab) in July ...

Alzheon's Alzheimer's drug showed nominal benefit in a subgroup of patients who suffer with mild cognitive impairment.

An extended study after a primary trial supports using the anti-amyloid drug lecanemab (Leqembi) for up to 36 months in ...

The risk for amyloid-related imaging abnormalities in early-stage Alzheimer’s disease is primarily driven by the ...

Additionally, the study showed that the majority of patients receiving Leqembi were diagnosed with mild Alzheimer's disease, compared with mild cognitive impairment (MCI). In general, anti-Aβ ...

Within the past few years, the FDA approved two groundbreaking drugs that in trials were shown to reduce brain plaque by 27% ...

Roche’s Brainshuttle tech shows promise in Alzheimer’s treatment, enabling better drug delivery to the brain in trials.

Eisai and Biogen's Alzheimer's therapy Leqembi will be priced at $26,500 per year – a little less than misfired predecessor Aduhelm – after getting conditional authorisation for the drug from ...

Sporting a bright yellow "End Alz" jersey, a white baseball cap and blue-green neck warmer, Ralph Carmona bounced up and down on his wiry legs, warming up for a run on a sunny but brisk morning in ...

The top-line results of the APOLLOE4 trial showed that valitramiprosate (ALZ-801) was unable to slow down cognitive decline ...

A pause to NIH funding has researchers scrambling for contingency plans at the University of Washington’s Alzheimer’s Disease ...

Valiltramiprosate was no better than placebo at slowing cognitive decline, as assessed by ADAS-Cog13, in the latest phase 3 ...